Drug ID: 1d00000135
Drug Name: Atovaquone
Generic Names: Mepron
Category: Miscellaneous Anti- Infectives
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Adult: The recommended oral dose is 1,500 mg (10 ml) once daily, administered with a meal.
Recommended In: This medication is an antibiotic, prescribed for Pneumocystis pneumonia (PCP), Toxoplasmosis and also for malaria treatment in combination with proguanil. The medication inhibits the reproduction of the protozoan that causes the disease.
Directions For Use: It comes as a suspension to take by mouth with food.
Storage: Store it at room temperature, and in an airtight container. Keep away from children.
Dosage Forms: Suspension
Side Effects: Most Common- Allergic reactions like rash, fever, sore throat, nausea, vomiting, increased cough and anemia.
Central Nervous System- Headache, weakness, dizziness, depression, anxiety and sleeplessness.
Gastrointestinal- Abdominal pain.
Respiratory- Difficulty in breathing and inflammation of nose.
Miscellaneous- Flu-like syndrome, itching and muscle pain.
In Case of Overdose: There is no known antidote for atovaquone, and it is currently unknown if atovaquone is dialyzable.
Avoid If: Caution should be exercised in patients with history of stomach, intestinal problem, lung disease, liver impairment, allergy, elderly, children, during pregnancy and breastfeeding.
Take full course of treatment.
Drug Interaction: Atovaquone is highly bound to plasma protein ( > 99.9%). Therefore, caution should be used when administering Atovaquone concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur. The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/mL), nor is the binding of phenytoin affected by the presence of atovaquone.
Coadministration of rifampin and Atovaquone Suspension results in a significant decrease in average steady-state plasma atovaquone concentrations. Alternatives to rifampin should be considered during the course of PCP treatment with Atovaquone.
Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin. No interaction trials have been conducted with Atovaquone and rifabutin.